Gottlieb's Views on Drug Safety Versus Speed to Market by John Mack Previously Pharmaguy published on 2017-04-06T18:22:45Z Where’s the balance between drug safety and speeding up clinical trials to bring drugs to market faster? That was a major issue underscoring the testimony of Dr. Scott Gottlieb, president Trump’s nominee to head the FDA, before the U.S. Senate Committee on Health, Education, Labor and Pensions.